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Abstract 
 
      Statins are a class of drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMGcoA) reductase, a critical enzyme in the mevalonate pathway.  Several reports 
document that statins may prevent different human cancers.  However, whether or not 
statins can prevent cancer is controversial due to discordant results.  One possible 
explanation for these conflicting conclusions is that only some tumors or specific 
statins may be effective.  Here we demonstrate in an in vivo transgenic model that 
atorvastatin reverses and prevents the onset of MYC-induced lymphomagenesis, but 
fails to reverse or prevent tumorigenesis in the presence of constitutively activated K-
Ras (G12D). Utilizing phospho-protein FACS analysis, atorvastatin treatment was 
found to result in the inactivation of the Ras and ERK1/2 signaling pathways associated 
with the dephosphorylation and inactivation of MYC. Correspondingly, tumors with a 
constitutively activated K-Ras (G12D) did not exhibit dephosphorylation of ERK1/2 
and MYC.   Atorvastatin’s effects on MYC were specific to the inhibition of HMG-
CoA reductase, as treatment with mevalonate, the product of HMG-CoA reductase   
activity, abrogated these effects and inhibited the ability of atorvastatin to reverse or 
suppress tumorigenesis.  Also, RNAi directed at HMGcoA reductase was sufficient to 
abrogate the neoplastic properties of MYC-induced tumors.  Thus, atorvastatin, by 
inhibiting HMGcoA reductase, induces changes in phospho-protein signaling that in 
turn prevent MYC-induced lymphomagenesis. 
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 Introduction 
          Cancer is largely caused by genomic events which result in the activation of 
oncogenes or the loss of tumor suppressor genes 
1. The targeted inactivation of 
oncogenes may be a specific and effective therapy for treating certain malignancies 
2,3. 
Experimental results in animal models validate the notion that the targeted inactivation 
of a single oncogene can be sufficient to reverse tumorigenesis 
4. Drugs that target 
specific proteins have been identified and shown to be effective in the treatment of 
certain cancers 
5-21, which indicates that some neoplasms are susceptible to therapies 
that target their molecular causes. However, cancers can escape dependence upon 
oncogenes, as observed in animal models as well as in human patients 
21-23.  Thus, the 
best targets may not be the suspected oncogenes but rather proteins essential to multiple 
signaling or metabolic pathways required for tumor maintenance.   
     MYC is one of the oncogenes most commonly associated with human cancer 
24.  
Experimentally, the inactivation of MYC has been shown to induce sustained tumor 
regression in transgenic mouse models of many different tumors, suggesting that MYC 
may be a good target for cancer treatment 
25-28.  However, MYC, as a transcription 
factor, is not easy to target directly with small molecules.  Thus, rather than directly 
targeting MYC, it might be possible to inactivate MYC through the disruption of 
upstream regulatory signaling molecules such as those in pathways regulated by Ras 
and ERK1/2 
29,30.   
     The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMGcoA) reductase is rate-
limiting in the mevalonate pathway 
31 (Supplementary Figure 1a) and is required for 
the synthesis of isoprenoids that play fundamental roles in the regulation of cell 
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signaling. Isoprenoid groups are necessary for  the post-translational modification of 
proteins, including Ras, that regulate cellular proliferation and apoptosis 
32-34.  Statins 
are a class of drugs that inhibit HMGcoA reductase 
35 and have been widely used to 
reduce cholesterol levels  for the prevention of atherosclerosis 
36.  Statins have been 
reported to have potent anti-tumor properties both in vitro and in vivo 
37-46.  Several 
reports document that statins may prevent different cancers.  Most notably, one study 
documented a 50% decrease in the incidence of colon cancer 
47,48.  However, two recent 
large meta-analyses suggest that statins may not prevent malignancy 
49,50.   
            We hypothesized that the anti-neoplastic effects of statins may be mediated by 
inhibiting the function of discrete oncogenic signaling pathways, which implies that 
these drugs may only demonstrate efficacy in a subset of molecularly-defined tumors. 
Consistent with this possibility, we found in a transgenic mouse model that atorvastatin 
can reverse and prevent MYC-induced lymphomagenesis but failed to do so in tumors 
induced in the context of constitutively activated K-Ras (G12D). We have examined 
signaling pathways by phospho-protein FACS analysis and found that atorvastatin 
induces a specific phospho-protein signature by shutting down specific signaling 
networks required to sustain MYC activation. 
 
Materials and Methods 
Transgenic mice 
The "Tet-system" was used to generate transgenic mice that conditionally express the 
human MYC cDNA in T-cell lymphocytes, as previously described 
19,48. Dr. Harold 
Varmus (Memorial Sloan-Kettering Cancer Center, NY) kindly provided the TRE-Ras 
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(murine K-Ras (G12D)) transgenic line. Tumorigenesis experiments were performed as 
previously described 
74. 
 
Transgenic cell lines 
Single cell suspensions were generated from tumors of MYC-overexpressing mice by 
mechanical disruption. Cells were grown in RPMI 1640 supplemented with 10% FCS, 
β-mercaptoethanol, glutamine, and pen-strep. Early passages of the cell lines were used 
for the experiments described. 
 
Histology  
Tissues were fixed in 10% buffered formalin and embedded in paraffin. Five µm 
sections were stained with haematoxylin and eosin. 
 
TUNEL Assay 
Apoptotic cells were detected by the TUNEL assay in situ death detection kit (Roche 
Diagnostic, IN) as described by supplier. Cells were counterstained with DAPI (Vector 
Lab, CA).  
 
Proliferation Assay 
Cells were grown in their respective media requirements and cultures were pulsed for 
18 h with 1 µCi per well of [
3H]thymidine. Cells were harvested and [
3H]thymidine  
incorporation was measured. Results are shown as the mean of triplicate experiments 
with standard error mean (s.e.m) given as a percentage. 
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Cholesterol Assay 
Cellular cholesterol was detected using the Amplex Red Cholesterol Assay Kit 
(Molecular Probes, A12216) as suggested by the manufacturer. 
 
Flow Cytometry 
Intracellular probes for active kinases were made by conjugating phospho-specific 
antibodies to the Alexa Fluor dye series as described and were used in phospho-protein 
optimized conditions
61,62. Cells (1x10
6 cells/ml) were fixed in tissue culture plates in 
2% PFA, for 15 min at 37
0C and permeabilized with methanol and stored at -20
0C until 
stained. Cells were seeded into 96 well plates, washed in PBS, and stained with 
antibody cocktails in 4% FCS for 30 min, washed 3 times and then processed for flow 
cytometry. All centrifugation, staining, and flow cytometry processes were performed 
on ice with ice-cold buffers using pre-titered antibodies at optimal antibody 
concentrations and fluorophore FTP ratios 
62. Flow cytometry data are representative of 
3 independent experiments. Four-color flow cytometry was collected on a 
FACSCalibur machine. Multi-color flow cytometry was collected on a FACSCAN or 
FACSARIA. Data was analyzed using FlowJo software (Treestar). Phosphorylated 
kinase clustering was performed using Hierarchical Cluster Explorer. 
 
 
 
Antibodies 
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  Phospho-specific antibodies to STAT5(Y694), STAT1(Y701), STAT3(Y705), 
STAT3(S727), ERK1/2 (T202/Y204), p38(T180/Y182), Plcγ1(Y783), Lck(Y505) 
conjugated to alexa488, PE, or alexa647 were from BD-Biosciences. Phospho-specific 
antibodies raised against IκB-α (S32/36), Ikkα(S176/180), cRaf(S259), cRaf(S338), 
cRaf(S621), Elk(S338), JNK(Y183/T185), AKT(S473), AKT(T308), cJun(S73), 
Bad(S112), Bad(S136), Mek(T394), Mek(S298), NFκB(S259) and Vav1(Y160) were 
from Biosource International. Antibodies against HMGcoA reductase and MYC were 
from Upstate Technologies. Cleaved Caspase-3-PE, cleaved PARP-FITC, Bad-FITC, 
Bcl2-Fitc, Annexin-Cy5 were from BD-Biosciences.  Alexa fluor dye series 405, 430, 
488, 546, 568, 647, 700 were from Molecular Probes. 
      Antibodies used in Western blot analysis: ERK1/2 (9102), p-ERK1/2 (4377), p-Raf 
(9427) were from Cell Signaling Technology; Akt, p-Akt(S473) were from BD-
Biosciences. Antibodies against α-tubulin, (5280) and Bax were from Upstate cell 
signaling solutions, β-actin - from Sigma (A2668),  Ras - from BD Biosciences 
(610002), DNA J - from Lab Vision Corp. (MS-225-p), Caspase 3 and cleaved Caspase 
3 - from Cell Signaling Technologies (9662), Rho A - from Santa Cruz Biotech. (sc-
418), Rho B - from Santa Cruz Biotech. (sc-1) Rap1 - from Santa Cruz Biotech. (sc-65) 
and Rac 1 (sc-217) - from Santa Cruz Biotechnology. Antibodies against HMGcoA 
reductase (07-572) - from Upstate Technologies, and p-c-MYC (9401) - from Cell 
Signaling Technology. 
 
Immunoblotting 
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Cell extracts were prepared by washing 2x10
6 cells (treated as indicated) in ice cold 
PBS and harvesting in lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 
mM EGTA, 1% Triton X-100, 2.5 mM Na2PO4, 1 mM β-glycerolphosphate, 1 mM 
Na3VO4,  1  µg/ml Leupeptin, 1 mM PMSF, protease inhibitor cocktail tablet 
(Boehringer Mannheim).  Extracts were centrifuged at 14,000 RPM (5 min, 4
0C) and 
10-20 µg (BCA protein assay (Pierce)) was immunoblotted using standard procedures. 
Blots were incubated with the indicated antibodies and developed using ECL 
(Amersham). Immunoblots were stripped by incubating with stripping buffer (62.5 mM 
Tris, pH 6.8, 10% SDS, 1% β-mercaptoethanol) (30 min, 55°C) and re-probed.  
Atorvastatin treatment  
Atorvastatin (Lipitor Pfizer Inc., prescription formulation) was put into suspension in 
PBS. Atorvastatin was administered orally in 0.5  ml doses weekly using 20-mm 
feeding needles (Popper and Sons Inc.). PBS was administered as control. Purified 
atorvastatin (Sequoia Research Products Inc) was used for in vitro studies. 
Viral Infections 
Ad-Myc
WT, Ad-Myc
S62A and Ad-Myc
T58A viruses were kindly provided as a gift from 
Dr. Rosalie C. Sears (Oregon Health & Science University, OR). HeLa cells were 
infected as previously described 
67. In brief, Hela cells were infected with virus by 
incubation in DMEM at 37 °C for ~60 min at a cell-to-volume ratio of 4x10
5 cells/ml. 
Cells were monitored during infection. Media was replaced after infection and the cells 
were further incubated at 37 °C. Infection was confirmed by GFP expression and cells 
were then treated with atorvastatin. 
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Quantitation of mRNA by real time PCR 
Total RNA from lymphoma cells was extracted and purified using TRIzol® reagent 
(Invitrogen, Carlsbad, CA) and RNA was quantified by spectrophotometer (Beckman 
Coulter, Fullerton, CA ). After DNase I digestion (amplification grade, 18068-0158, 
Invitrogen) 2 µg of total RNA was reverse-transcribed by Superscript II reverse 
transcriptase (Invitrogen) according to the manufacturer's protocol using random oligo-
d(T) as primers. Real-time PCR analysis was carried out on an ABI Prism 7900HT 
system (Applied Biosystems, Foster City, CA). PCR conditions were 95ºC for 10 min 
followed by 40 cycles of 95ºC for 15 s and 60ºC for 1 min. Each reaction contained 
cDNA (10 ng), primers (800 nM) and SYBR® Green QPCR Master Mix (Stratagene, 
La Jolla, CA) in a total volume of 6 µl. Primers were generously provided by Dr. Bruno 
Amati (European Institute of Oncology, Milan, Italy). All samples were analyzed in 
triplicates and were quantified using a standard curve generated by serial dilution of 
cDNA pooled from non-treated and treated lymphoma cells. The level of each mRNA 
was normalized to that of ubiquitin. Student T-test was performed to compare the 
treated and non-treated tumors; 1) MYC ON versus MYC OFF 2) MYC ON versus 
MYC ON + atorvastatin 3) MYC ON versus MYC ON + Mevalonate 4) MYC ON 
versus MYC ON + atorvastatin + Mevalonate. Results were visualized using TreeView 
(©Eisen). 
 
 
Cell fractionation and protein isolation. 
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Cell fractionation studies to determine RAS localization were performed as previously 
described 
67.  In brief, 200 million cells of atorvastatin treated vs. untreated cells were 
washed three times in PBS and homogenized in lysis buffer (1 mM EDTA, 20 mM
 
Tris-HCl, pH 7.4).  Lysate was centrifuged
  at 31,200 RPM using a Beckman 
ultracentrifuge. The supernatant
  (soluble fraction) was concentrated using a 10 K 
molecular limit
 Nanosep centrifugal device (Pall Life Sciences). The membrane
 pellet 
was solubilized in 2x immunoprecipitation buffer (0.15
 M NaCl, 1% Triton X-100, 
0.5% sodium deoxycholate, and 0.1%
 SDS, 10 mM Tris-HCl, pH 7.5) and centrifuged 
at 15,000 RPM to
 obtain a clarified supernatant. Protease and phosphatase inhibitors 
were included
  in all buffers. All homogenization, immunoprecipitation and 
centrifugation steps were performed using fresh material, on ice with ice cold buffers.  
The concentration of proteins
 in each sample was determined using a BCA assay kit 
(Pierce
 Chemical Co.).  
 
Results 
Atorvastatin is effective in reversing and preventing MYC-induced lymphomagenesis 
     Whether or not statins can prevent cancer in humans is controversial 
8,43,48-52.  
One possible explanation for the discordant results is that only specific tumors or 
certain statins may be effective.  We speculated that the efficacy of statins in treating 
cancer may be more easily defined in transgenic models of tumorigenesis. Previously, 
we have described a conditional transgenic model system for MYC-induced 
lymphomagenesis 
53. The model system has the useful feature that the MYC transgene 
is conditionally regulated through the “Tet-system” via administration of doxycycline 
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where the Ig heavy
 chain enhancer and the SR α promoter (EµSR) elements were used 
to drive expression of the Tet-regulatory elements. Thus, MYC is overexpressed in the 
hematopoietic cells in the absence of doxycycline and is repressed upon addition
 of 
doxycycline to the drinking water.  MYC overexpression results
 in the development of 
T-cell lymphomas.  Treatment of tumor bearing mice with doxycycline results in MYC 
inactivation and in the regression of
 the tumors. 
          To gain more insight into the mechanisms by which statins induce proliferative 
arrest and apoptosis in tumors, we first evaluated the in vitro efficacy of statins in our 
MYC-induced T-cell lymphomas. We tested the effect of several commercially 
available statins on the MYC-induced T-cell lymphomas. Atorvastatin was found to be 
more potent than simvastatin and lovastatin whereas pravastatin was ineffective in 
inducing proliferative arrest (Figure 1a). Pravastatin is known to bind less effectively 
to HMGcoA reductase, which perhaps accounts for the lack of effect on tumor cells 
when compared to the other statins tested 
54. Atorvastatin was found to induce a dose-
dependent growth inhibition in the MYC-induced T-cells lymphomas (Figure 1b). The 
majority of the tumor cells ceased to proliferate when treated with 10µM atorvastatin. 
Similar results were seen in 6 independently generated transgenic tumor cell lines. 
Notably, tumors generated from mice in which p53 was knocked out or BCL2 was 
overexpressed also exhibited apoptosis upon statin treatment (data not shown). The 
concentration of atorvastatin used in the experiment is comparable to the plasma levels 
achieved in treated humans 
55. The downstream product of HMGcoA reductase, 
mevalonate, prevented atorvastatin from inhibiting growth of tumor cells (Figure 1c).  
The effect of atorvastatin (10µM) was compared to MYC inactivation in the MYC-
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induced tumor cells. Atorvastatin treatment of MYC-induced transgenic lymphomas in 
vitro was associated with proliferative arrest and apoptosis at higher levels than those 
obtained through MYC inactivation (Figure 1c, Supplementary Figure 2, 3).   
     To evaluate the efficacy of atorvastatin for the treatment of cancers arising in vivo, 
we examined the ability of atorvastatin treatment to induce tumor regression in the 
transgenic model of MYC-induced lymphomagenesis 
53. Mice with tumor burden were 
either left untreated, treated with doxycycline to inactivate the MYC transgene, or 
treated daily with various doses of atorvastatin given orally.  Untreated mice rapidly 
succumbed to tumor burden (Figure 1d, e), whereas treatment with atorvastatin, similar 
to inactivation of MYC, induced the rapid regression of tumors within one week of 
treatment and increased survival (1mg/kg (p<0.002; [n=5]) and 10mg/kg (p<0.02; 
[n=5])) (Figure 1d, f). Mice treated daily with 100 mg/kg were unable to tolerate 
therapy for more than 2 weeks. Treatment with atorvastatin resulted in the apoptosis of 
tumor cells in vivo, as observed by examination of histological specimens and measured 
by TUNEL assay (Figure 1g-j).  Thus, atorvastatin can reverse MYC-induced 
tumorigenesis even in established tumors in vivo.     
     Our results suggested to us that atorvastatin may also be able to prevent MYC-
induced tumorigenesis. Cohorts of mice were either treated with doxycycline to 
suppress MYC expression or not treated with doxycycline and treated with varying 
doses of atorvastatin, or atorvastatin plus mevalonate (Figure 2a).  As expected, 
transgenic mice not treated with doxycycline developed tumors with a frequency of 
100% and a mean latency of tumor onset of 13 weeks 
26,53. As we have previously 
shown, inactivation of MYC with doxycycline [n=5] completely prevented 
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tumorigenesis 
26,27,53. Since mice treated daily with 100 mg/kg of atorvastatin were 
unable to tolerate therapy for more than 2 weeks, we now treated mice with 100 mg/kg 
2-3 times per week. Thus, we were able to prevent the acute toxicity observed with the 
daily treatment. Tumor onset was largely prevented by atorvastatin administered orally 
2-3 times weekly (100mg/kg) (p<0.0001; [n=16]). Importantly, atorvastatin failed to 
prevent tumorigenesis in mice treated with mevalonate ((20mg/kg); [n=13]) suggesting 
that inhibition of HMGcoA reductase was responsible for preventing tumorigenesis.  
These mice had a survival similar to mice expressing MYC that were not treated with 
statins. When treated with lower doses of atorvastatin (1 mg/kg; [n=16] or 10 mg/kg; 
[n=10]), 30% of mice remained disease-free, suggesting that there may be a dose-
dependent ability of atorvastatin to prevent tumorigenesis.  Thus, atorvastatin, 
presumably through inactivation of HMGcoA reductase, induces a dose-dependent 
inhibition of MYC-induced tumorigenesis.  
     We observed that mice did not tolerate higher doses (100 mg/kg) 3 times per week 
for more than 20 weeks due to increased mortality. We could not attribute this effect to 
changes in liver or kidney function or to rhabdomyolysis, which are all potential toxic 
effects that are seen in humans (data not shown).  Reported doses used in 
pharmocokinetic studies of mice range from 100-800 mg/kg/day 
56. In C57Bl6 mice, 
the toxic dose is 800 mg/kg/day.  In humans the toxic dose is above 80mg/day
57. 
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Atorvastatin can be used in vitro or in vivo to purge pre-neoplastic or neoplastic cells 
     Next, to evaluate the ability of atorvastatin to specifically target tumor cells, bone 
marrow cells from MYC transgenic mice either before or after tumor onset were treated 
with atorvastatin. Lethally-irradiated syngeneic, non-transgenic mice were transplanted 
with bone marrow from newly weaned MYC-overexpressing transgenic mice prior to 
tumor formation (4-5 weeks old).  Atorvastatin treatment of these mice delayed tumor 
onset by 20 weeks (p<0.0001; [n=5]) (Figure 2c).  The in vitro atorvastatin treatment 
of bone marrow from mice with tumor burden for 30 or 48 hours, but not 24 hours, was 
sufficient to delay tumor onset by over 30 weeks (30hr  (p<0.002; [n=5]), or to 
completely prevent tumor onset (48hr (p<0.0001; [n=5]), respectively (Figure 2d). 
Thus, atorvastatin may be effective in delaying tumor onset of pre-neoplastic cells or in 
purging bone marrow of neoplastic cells. 
     We also found that even the transient treatment of transgenic mice with atorvastatin 
for 6 weeks [n=13] delays tumor onset by over 40 weeks compared with untreated mice 
(p<0.0001; [n=16]) in a manner similar to what is observed during transient MYC 
inactivation [n=9] in lymphoid tumors (Figure 2e).  To explain these results, we found 
in vivo that atorvastatin treatment induced apoptosis in MYC-overexpressing 
thymocytes prior to tumor formation (Supplementary Figure 5). To interrogate the 
kinetics of tumor cell elimination, bioluminescence imaging was performed using 
methods we have described 
26.  MYC inactivation and atorvastatin treatment induced a 
similar degree of tumor regression, albeit statins induced tumor regression with delayed 
kinetics (Supplementary Figure 6). Hence, atorvastatin appears to prevent MYC from 
initiating tumorigenesis by inducing apoptosis in MYC-activated pre-neoplastic cells. 
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Atorvastatin inactivates multiple signaling pathways  
     To account for the dramatic affects of atorvastatin on the reversal and prevention of 
MYC-induced tumorigenesis, we reasoned that atorvastatin may be inhibiting key 
effectors required to maintain MYC activation and function. Mevalonate is required for 
cholesterol synthesis and for the prenylation and activation of many proteins 
63-65. The 
inhibition of HMGcoA reductase inhibits the synthesis of mevalonate (Supplementary 
Figure 1). Atorvastatin treatment induced a modest reduction of 10-30% in cellular 
cholesterol levels of MYC expressing lymphoma cells (Figure 3a).  Atorvastatin 
treatment of the MYC-induced lymphomas was found to influence the prenylation of 
several proteins (Figure 3b). Within 24 hours of atorvastatin (10µM) treatment, 
farnesylation of Ras and DNAJ was inhibited.  A shift in the mobility of these proteins 
was observed by Western blot analysis.  
          To evaluate if this shift was similar to the one resulting from defarnesylation 
mediated by FTIs, the specific farnesyltransferase inhibitor FTI-277 was administered 
and shown to induce the same change in protein migration (Figure 3b). In addition, 
atorvastatin affected the geranylation process of several proteins such as Rap1, RhoA 
and RhoB, which was confirmed by demonstrating similar changes in protein mobility 
after treatment with the specific geranylgeranyltransferase inhibitor GGTI-298 (Figure 
3b). A shift in the mobility was observed for Ras, DNAJ and Rap1. However, RhoA 
and B showed increased levels of expression after atorvastatin treatment, an effect 
previously described as translational and post-translational due to the increase of de 
novo protein synthesis and decrease in the Rho protein degradation following treatment 
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with statins 
66. We confirmed that atorvastatin treatment decreased membrane-bound 
Ras and increased the accumulation of Ras in the cytoplasm of the cell as early as 6 
hours after treatment, as would be expected with decreased Ras prenylation (Figure 
3c). Mevalonate reversed the effects of atorvastatin, suggesting that the changes may be 
mediated through the inhibition of HMGcoA reductase function. Indeed, it has recently 
been shown that atorvastatin mediates its affects on lymphocyte biology by perturbing 
prenylation 
67. As a negative control, we demonstrated that the suppression of MYC 
expression did not affect the post-translational modification of these proteins. Thus, 
atorvastatin influenced the prenylation of several signaling molecules, as has been 
described previously 
63-65. 
 
Atorvastatin Fails to Prevent Ras-associated Lymphomagenesis 
          To evaluate if atorvastatin specifically reverses and prevents MYC-induced 
tumorigenesis by perturbing protein pathways regulated by post-translational 
modification 
32-34,  we examined how atorvastatin affects tumorigenesis induced by the 
overexpression of MYC together with a potent oncogene that may regulate MYC 
activation. Ras mutations that often occur in human tumors did not occur spontaneously 
in the MYC overexpressing mice tumors (data not shown). The G12D mutation in K-
Ras causes the protein to be constitutively activated which then activates the MAP 
kinase pathway and subsequently ERK1/2 that in turn phosphorylates and activates 
MYC. Although Ras requires prenylation to localize to the plasma membrane and 
become activated, several recent papers have described that constitutively activated Ras 
can mediate oncogenic effects without localization to the plasma membrane 
58-61.  We 
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therefore hypothesized that the oncogenic activity of MYC would not be affected by 
HMGcoA reductase inhibition in the presence of constitutively activated, mutated K-
RAS (G12D). 
          Cohorts of transgenic mice were generated that overexpressed both MYC and 
mutated K-Ras (G12D)
62 using the “Tet-system”.  In contrast to tumors induced by 
MYC alone, tumorigenesis was not prevented by atorvastatin when MYC activation 
was combined with mutated K-Ras (G12D) (Figure 2b).  Moreover, tumors caused by 
MYC and mutated K-Ras (G12D) did not show any survival advantage with 
atorvastatin treatment compared with untreated mice (Supplementary Figure 4). 
Therefore, atorvastatin reverses and prevents lymphomagenesis associated with MYC, 
but not in the presence of mutated K-Ras (G12D).  
 
Phospho-protein FACS analysis of the effects of atorvastatin on cell signaling 
   To broadly evaluate the effects of atorvastatin on changes in cell signaling as a 
result of alterations in protein prenylation and cellular cholesterol content, several 
signal transduction pathways were surveyed using a multi-parameter phospho-
proteomic approach 
68-70 to assess changes in the phosphorylation status of multiple 
signaling proteins after treatment. Single cell analysis of phosphorylation changes was 
accomplished by intracellular staining of 56 different phosphorylation epitopes using 
directly conjugated multi-color phospho-specific antibodies at 11 time points following 
treatment. The geometric means of fluorescent intensity values were computed relative 
to the non-treated media control and analyzed using heat-map visualization tools to 
identify patterns of phosphorylation.  
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     In the presence of atorvastatin, significant changes for 19 epitopes were observed 
after 24 and 36 hours of treatment. A de-phosphorylation of ERK1/2, Vav, p38, JNK, 
and cRaf was observed within 24 hours (Figure 3d see*, 3e), suggesting that MAPK 
signaling proteins and their transcriptional targets such as Elk-1 were being de-
activated. Critically, phosphorylation of Akt at serine 473 and threonine 308, known to 
be required for cell survival 
71, dropped significantly by 36 hours. Interestingly, 
phosphorylated proteins (JNK, Bad, Raf, PLCγ, Stat5) that had decreased 
phosphorylation at 24 hours of treatment regained phosphorylation at 36 hours, 
suggesting a compensatory mechanism or program had been initiated. By 36 hours, 
atorvastatin-treated cells became Annexin-V positive (Supplementary Figure 3). By 
contrast, in the presence of mevalonate, dephosphorylation of ERK1/2, Vav1, AKT, 
and IKKα that resulted from atorvastatin treatment was reversed, indicating that the 
effects observed were due to the inhibition of HMGcoA reductase.  In addition, 
mevalonate also inhibited cell death induced by atorvastatin (Supplementary Figure 
3). Thus, the inhibition of mevalonate biosynthesis via atorvastatin inactivation of 
HMGcoA reductase results in the rapid dephosphorylation of many integral signaling 
components of the ERK1/2 MAPK pathway (Raf, Mek, ERK1/2, Elk, p38, JNK), cell 
survival pathways (Akt), as well as T cell signaling molecules (Vav, IKKα, NF-κB) 
and several transcription factors (STATs).  Erk 1/2 and Akt changes were confirmed by 
Western blot (Figure 3d-f).  These changes could reflect the effects of atorvastatin on 
prenylation and/or lipid rafts. 
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Atorvastatin treatment results in the dephosphorylation and inactivation of MYC in 
murine and human cell lines 
     Many of the signaling pathways affected by atorvastatin treatment are involved in 
the regulation of MYC (Supplementary Figure 7).  In particular, Ras and ERK1/2 are 
known to be required for MYC phosphorylation 
72,73. Atorvastatin treatment did not 
affect MYC protein levels, but did decrease MYC phosphorylation (Figure 4a). A 
temporal analysis of ERK1/2 and MYC phosphorylation upon atorvastatin treatment 
indicated that atorvastatin treatment first inhibits ERK1/2 phosphorylation followed by 
the loss of phosphorylation of MYC at S62,T58. Phosphorylation of S62 is required for 
MYC activation. Differences in phosphorylation between non treated and atorvastatin 
treated cells was also observed by mass spectrometry (data not shown). At 24 hours, 
cells exhibit increased levels of cleaved caspase 3, an indicator of the initiation of 
apoptosis (Figure 4b). Importantly, atorvastatin treatment of a human Burkitt’s 
lymphoma cell line, ST486, induced the loss of phosphorylated ERK1/2 and MYC and 
subsequently induced the cleavage of caspase 3 and cell death (Figure 4c, 
Supplementary Figure 8).  Hence, atorvastatin treatment of murine and human MYC-
induced tumors resulted in the dephosphorylation of MYC followed by an increase in 
levels of cleaved caspase 3. 
     To evaluate whether the dephosphorylation of MYC was associated with decreased 
transcriptional function, a temporal analysis of the expression of a known MYC target 
gene, ODC, was performed.  Notably, the loss of MYC phosphorylation occurred after 
18 hours of atorvastatin treatment and was found to also be associated with the loss of 
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expression of ODC as measured by Western blot analysis (Figure 4d). Furthermore, we 
compared the ability of atorvastatin to affect MYC related gene transcription by QT-
PCR.  A series of target genes strongly associated with MYC’s function were 
examined, including cell cycle regulatory genes (cyclin A, cdc4, cdc25a, nuclear 
protein p120, nucleolin and p21) and genes associated with cell metabolism (GPAT, 
DHFR and CAD).  We found that after atorvastatin treatment, 18 of these 29 MYC 
target genes exhibited a downregulation in gene expression similar to those following 
the inactivation of MYC expression by doxycycline (Figure 4e). The co-treatment with 
mevalonate and atorvastatin was shown to reverse the decrease in the gene expression 
induced by atorvastatin treatment. On the other hand, while MYC inactivation induced 
an upregulation in 6 of the 29 genes analyzed (p21, p18, Gadd45, cdc44, cyclin D3 and 
GAD143), the expression of the remaining 5 genes was not altered by atorvastatin 
treatment. This difference in the effect of atorvastatin on gene transactivation and 
transrepression, suggest that phosphorylation may be essential for MYC’s 
transactivational function but not sufficient for MYC’s transrepressional function. This 
suggests that the atorvastatin treatment compromises MYC’s transactivation function 
but may not affect MYC’s transrepressional function. Therefore, atorvastatin treatment 
of MYC-induced tumor cells affects MYC regulated transcriptional activity. 
 
Atorvastatin fails to inactivate MYC in the presence of constitutively activated K-Ras 
(G12D) 
     Since Ras regulates signaling pathways that are required to activate MYC through 
phosphorylation, we considered the possibility that constitutively activated K-Ras 
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(G12D) was preventing atorvastatin from inactivating MYC signaling pathways. As 
predicted, atorvastatin treatment of MYC-induced tumors that had constitutively 
activated K-Ras (G12D) failed to exhibit decreased phosphorylation of ERK1/2 or 
MYC  (Figure 5a); continued to express the MYC target gene, ODC (Figure 5a); and 
failed to undergo complete cell cycle arrest (Figure 5b). Thus, the presence of a 
constitutively activated K-Ras (G12D) prevented atorvastatin from inducing MYC 
dephosphorylation and regression of tumors overexpressing MYC.   
 
Increased MYC expression potentiates sensitivity of HeLa cells to atorvastatin 
     Our results suggested the possibility that MYC overexpression and phosphorylation 
generally sensitizes cells to statins. Since the MYC expressing lymphoma cells are 
extremely hard to infect we conducted the following experiment in HeLa cells infected 
with three adenoviral constructs 
74.   The first construct contained wild-type murine 
Myc (Ad-MycWT).  The second contained a mutation in Myc at the S62 
phosphorylation site (Ad-MycS62A), which prevents Myc activation.  The third 
contained a mutation at the T58 phosphorylation site (Ad-MycT58A), which prevents 
dephosphorylation of Myc at S62 and mediates Myc degradation.  Introduction of wild-
type Myc, but not mutant Myc, enhanced the sensitivity of HeLa cells to apoptosis 
mediated by atorvastatin treatment (Figure 5c). Thus, atorvastatin treatment induces 
cell death in HeLa cells expressing wild-type Myc, but not in cells where crucial sites 
of Myc phosphorylation were disrupted.  
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HMGcoA reductase is required for tumor cell survival 
          Our results suggested that HMGcoA reductase was required for MYC-induced 
tumor maintenance.  We validated that atorvastatin treatment as well as MYC 
inactivation resulted in decreased levels of HMGcoA reductase protein levels but not in 
gene expression (Supplementary Figure 9). We targeted HMGcoA reductase with 
specific RNAi oligomers (Dharmacon RNA Technologies). We confirmed that 
transfection with HMGcoA reductase-specific RNAi decreased HMGcoA reductase 
protein levels, as measured by Western blot analysis and by FACS analysis after 18 
hours of transfection (Figure 6a). Thirty hours following transfection, a decreased 
viability of tumor cells was observed, as measured by trypan blue staining (Figure 6b). 
Following transfection with RNAi oligomers, we monitored individual tumor cells by 
FACS to assess HMGcoA reductase expression as well as phosphorylation of ERK1/2 
and MYC in the cells.  The targeted inactivation of HMGcoA reductase using siRNA 
specific-oligomers was sufficient to inhibit phosphorylation of ERK1/2 and MYC 
(siRNA/HMGcoA reductase, Figure 6d, orange), compared to control mock-
transfected cells, which had unaltered levels of HMGcoA reductase and phosphorylated 
ERK1/2 and MYC (Control, Figure 6c, blue/purple). Thus, the direct targeting of 
HMGcoA reductase by RNAi inhibits ERK1/2 and MYC phosphorylation in a manner 
that is sufficient to induce tumor cell death.  
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Discussion 
Statins are some of the most commonly prescribed medications in humans.  They have 
been in use now for almost two decades for the treatment of hypercholesterolemia and 
atherosclerosis 
36.  Statins have been shown by many investigators to have potential 
anti-neoplastic properties both in vitro and in vivo  
8,37-46. Many epidemiological studies 
have noted a significant reduction in the incidence of colon, breast, prostate and lung 
cancer in patients taking statins 
8,43,48,51,52.  Most notably, one report documented a 50% 
decrease in the incidence of colon cancer 
47. However, two recent large meta-analyses 
concluded that statins do not prevent cancer 
49,50.  To date, no explanation has been 
offered for these conflicting conclusions.  Our results suggest a possible explanation: 
perhaps only specific molecular signaling pathways associated with certain types of 
cancer may be sensitive to particular statins.  
     We provide evidence suggesting that atorvastatin can reverse and prevent tumors 
induced by MYC-overexpression but not tumors also carrying constitutively activated 
K-Ras (G12D).  The mechanism by which atorvastatin inhibits MYC is not clear.  One 
possible explanation raised from our results is that atorvastatin induces changes in 
protein prenylation and in the phospho-protein signature associated with the inhibition 
of several signaling pathways, such as Ras and ERK1/2, that are thought to be required 
for MYC phosphorylation and activation (Supplementary Figure 7) 
72,73,75.  
Atorvastatin caused the dephosphorylation and inactivation of MYC, which in turn was 
assossciated with the suppression of the expression of MYC target genes.   
Atorvastatin’s effects on the phosphorylation state of MYC were specific to the 
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inhibition of HMGcoA reductase, as treatment with mevalonate abrogated these effects 
and the ability of atorvastatin to reverse or suppress tumorigenesis. When treated with 
atorvastatin, tumors expressing constitutively activated K-Ras (G12D) did not exhibit 
MYC dephosphorylation or inactivation. Hence, from these results, we predicted and 
indeed showed that in the presence of constitutively activated K-Ras (G12D), 
atorvastatin failed to prevent tumorigenesis in MYC-induced tumors. 
     Our results are consistent with recent reports that constitutively activated Ras does 
not necessarily require prenylation to activate cellular signaling or function as an 
oncogene 
59,60.  Hence, given their putative mechanism of action, statins would not 
necessarily be expected to be fully capable of inactivating tumors with constitutively 
activated Ras that obviates the requirement for prenylation.  Our results suggest that 
MYC-induced lymphomas may be particularly sensitive to statins. Moreover, we show 
that atorvastatin resulted in ERK1/2 and MYC dephosphorylation in a Burkitt’s 
lymphoma cell line, a tumor type causally associated with MYC activation.   We 
recognize that these results in our transgenic model and in vitro in a human cell line 
will have to be validated in vivo in humans.  
          Our results raise the possibility that atorvastatin may be effective in preventing 
specific types of cancer.  Our findings also suggest the possibility that atorvastatin may 
be effective in purging these types of cancer cells from bone marrow before bone 
marrow transplantation. As also noted in previous studies, the dose of atorvastatin 
required to induce tumor regression of established tumors was different from the dose 
required to prevent tumorigenesis 
76.  Daily treatment with atorvastatin induced the 
regression of established tumors at doses of 1-10 mg/kg, which appears to be 
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comparable to doses used to treat hypercholesterolemia in humans 
77. By contrast, for 
prevention of MYC-induced tumorigenesis, we treated mice 3 times weekly with 
100mg/kg. HMGcoA reductase activity is inhibited in specific mouse strains only at 
daily doses of 100mg/kg and higher 
78. At a dose of 100mg/kg/day in male mice, the 
AUC is 10 times higher than that achieved in humans treated with 40mg/day. However 
when mice were given just one dose, the AUC is equivalent to that of humans implying 
that mice are unable to clear the drug as quickly as humans.  Perhaps these results 
would explain why continuous atorvastatin treatment is toxic to mice 
56.  Our results 
suggest that toxicity may also depend upon the strain of mouse.  In addition, 
mevalonate-derived intermediates have a higher affinity for enzymes involved in non-
sterol biosynthesis than cholesterol biosynthesis. Lower doses of statins have a far 
greater impact on cholesterol levels than on protein prenylation, but at higher doses 
affect protein prenylation
76.    Our results suggest that atorvastatin prevents MYC-
induced tumorigenesis by blocking HMGcoA reductase activity, because treatment 
with mevalonate completely abrogated tumor prevention.   
     Epidemiological studies have yet to describe differences among various statins or a 
dose response in their prevention of hematopoietic tumorigenesis 
8,43,48,51,52.  However, 
in these studies, patients usually did not receive atorvastatin but instead were treated 
with pravastatin or simvastatin.  Also, most studies did not specifically look at the 
affect of statins on hematopoietic tumorigenesis.  
            Statins appear to mediate their anti-neoplastic effects by inhibiting pathways 
downstream of HMGcoA reductase that are essential for MYC-associated oncogenic 
signaling pathways (Supplementary  Figure 7). Two observations confirm that the 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From  
  26
anti-neoplastic effects of statins are mediated through the inhibition of HMGcoA 
reductase.  First, mevalonate rescued tumors treated with atorvastatin.  Second, RNAi 
directed against HMGcoA reductase was sufficient to induce the loss of ERK1/2 and 
MYC phosphorylation in tumor cells in vitro. Specific pharmacologic inhibitors for 
geranylgeranylation (GGTI) and farnesylation (FTI) as well as inhibitors for ERK1/2 
and Akt are known to contribute to the loss of a neoplastic phenotype in tumors 
expressing wild-type Ras 
79,80.  In combination, these results suggest that statins may 
induce the loss of neoplastic properties by inhibiting multiple signaling processes that 
appear to be required for MYC-induced tumorigenesis. 
      Statins have yet to be described to have clinical efficacy in the treatment of cancer. 
Our results suggest that statins may be more capable of targeting early neoplastic cells, 
which tend to be less genetically complex, thereby preventing tumorigenesis. 
Specifically, our results suggest that MYC-associated lymphomagenesis may be 
prevented by treatment with atorvastatin. However, cancers appear to be capable of 
escaping dependence upon individual oncogenic signaling proteins, so we recognize 
that atorvastatin is likely to be more effective when combined with other therapies for 
the treatment of tumors 
22,81,82.    
          Finally, we have shown that by utilizing phospho-protein FACS profiling of 
multiple proteins in defined conditional transgenic models, we were able to 
demonstrate that MYC-induced tumorigenesis is sensitive to atorvastatin-mediated 
inhibition of HMGcoA reductase. The identification of the phospho-protein signature of 
signaling molecules may be useful in identifying drugs optimized for their anti-
neoplastic properties in specific oncogenic signaling states.   
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Figure legends 
Figure 1. Atorvastatin reversed MYC-induced tumorigenesis in vitro and in vivo. 
a) The influence of statins on cell proliferation was analyzed in murine lymphoma cell 
lines derived from a conditional transgenic model of MYC-induced lymphomagenesis 
utilizing the "Tet-system".  Tumor-derived cell lines were treated with 10µM 
atorvastatin (AT), 10µM simvastatin (SM), 10µM lovastatin (LOV) and 10µM 
pravastatin (PRA) and analyzed after 24 and 48 hours for survival.  Representative data 
is shown, for one of the six tumor-derived cell lines from our conditional MYC 
transgenic model. Growth was measured by [
3H]thymidine incorporation. Results are 
presented as stimulation index (SI), measured as the incorporation of [
3H]thymidine in 
the presence versus the absence of treatment. Experiments were performed in triplicate. 
b) Atorvastatin induced a dose-dependent inhibition of proliferation in MYC-induced 
tumors. Conditional transgenic lymphoma cell lines were generated using the "Tet-
system" by overexpressing MYC.  Tumor cells were treated with different doses of 
atorvastatin as indicated and growth was measured by [
3H]thymidine incorporation. 
Results are presented as stimulation index (SI), measured as the incorporation of 
[
3H]thymidine in the presence versus the absence of treatment with statins. Experiments 
were performed in triplicate. Cells were treated with different doses atorvastatin and 
analyzed after 24 and 48 hours (h) of treatment. Results are presented as the mean of 
three different experiments performed in triplicate. c) Atorvastatin inhibited 
proliferation and induced apoptosis in MYC expressing tumor cells. MYC lymphoma 
cells where MYC was expressed (MYC ON) or MYC was inactivated (MYC OFF) 
after doxycycline treatment (20 ng/ml) or in the presence of 10 µM atorvastatin (AT), 
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100 µM mevalonate (Mev) or 10 µM atorvastatin plus 100 µM mevalonate (AT + Mev) 
were pulsed with BRDU after 36 hours. Live cells were stained with PI and analyzed 
by FACS.   Results are presented as the mean of two different experiments. See also 
Supplementary Figures 2 &3. d) Survival of mice transplanted with a MYC-induced 
lymphoma cell line.  Mice were injected with tumor cells of one of the MYC-induced 
tumor derived cell lines and when moribund with tumor were either not treated (MYC 
ON (square)) or treated with doxycycline in their drinking water (100 µg/ml) to 
inactivate MYC (MYC OFF (circle)) or treated with atorvastatin after 5 weeks of tumor 
growth, at doses of 1mg/kg (triangle), or 10mg/kg (star). Each cohort consisted of 5 
mice. Significant difference in survival was determined by Chi square test (AT1mg/kg 
(p<0.002) and AT10mg/kg (p<0.02)). e)  Representative picture of mouse prior to 
treatment and f) after treatment with atorvastatin (1mg/kg) for 8 days. g) Histology of a 
tumor sections stained with haematoxylin and eosin, prior to treatment consisting of 
tumor cells with high nuclear to cytoplasmic ration and h) after treatment with 
atorvastatin where tumor cells appear to be apoptotic. i) TUNEL assay was performed 
to determine the presence of apoptotic cells prior to treatment and j) after treatment 
with atorvastatin. Representative data is shown. Similar results were observed for three 
different tumor derived lymphoma cell lines. 
 
Figure 2. Atorvastatin prevented the onset of MYC-induced lymphomagenesis. a) 
Atorvastatin treatment of mice expressing MYC. Kaplan-Meyer survival curves of 
transgenic mice conditionally overexpressing the MYC transgene in murine T-cell 
lymphocytes using the "Tet-system" (MYC ON; [n=16]) or treated with doxycycline to 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From  
  35
suppress MYC expression (MYC OFF; [n=5]).  Mice overexpressing MYC (MYC ON) 
were treated with atorvastatin 3 times weekly (MYC ON+AT1 - 1 mg/kg; [n=16]), 
(MYC ON + AT10 - 10 mg/kg; [n=11]), or (MYC ON+AT100 - 100 mg/kg; [n=16]) as 
indicated. Mice overexpressing MYC were treated with atorvastatin (100 mg/kg) and 
mevalonate (20 mg/kg) (MYC ON+AT100+Mev; [n=13]). Significant difference in 
survival was determined by Chi square test p<0.0001 (MYC ON +AT100 100mg/kg). 
b) Atorvastatin treatment of mice expressing MYC and constitutively activated K-Ras 
(G12D). Survival curve of mice overexpressing MYC alone ((MYC ON); [n=14]) or 
together with activated murine K-Ras (G12D) ((MYC/Ras ON); [n=8]) or treated 3 
times weekly with atorvastatin 100mg/kg (MYC/Ras ON+AT100 100mg/kg; [n=11]) c) 
Atorvastatin treatment prevents tumor onset in mice transplanted with bone marrow 
from MYC transgenic mice. Lethally irradiated mice were transplanted with bone 
marrow cells (5x10^6) pooled from 3 mice that overexpress MYC. Mice were treated 
with doxycycline to inactivate MYC (MYC OFF) [n=5], not treated with doxycycline 
(MYC ON) [n=5] or not treated with doxycycline but treated with atorvastatin (AT100 
100mg/kg; [n=5]) 3 times weekly. Significant difference in survival of atorvastatin-
treated mice compared to non-treated mice was determined by Chi square test 
(p<0.0001).  d)  In vitro purging  of bone marrow from MYC transgenic mice with 
atorvastatin prevents tumor development. Bone marrow of MYC-overexpressing mice 
with tumor burden was treated in vitro with atorvastatin (10 µM) for 24 hours [n=5], 30 
hours [n=5] or for 48 hours [n=5]. Treated or non-treated bone marrow cells (5x10^6) 
were injected into lethally-irradiated mice. Significant difference in survival was 
determined by Chi square test (24 hours; p>0.04, 30 hours; p<0.002, 48 hours 
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p<0.0001).  e) Transient treatment with atorvastatin delays tumor onset. Transgenic 
mice conditionally overexpressing MYC were either treated with doxycycline for 6 
weeks (MYC OFF 6 weeks, [n=9]) or not treated with doxycycline (AT 100 mg/kg 6 
weeks, [n=14]) but treated with atorvastatin at 100 mg/kg 3 times weekly for 6 weeks 
[n=13] when weaned.  The difference in survival of atorvastatin-treated mice was 
compared to that of non-treated mice, using Chi square test (p<0.0001). 
 
Figure 3. Atorvastatin-mediated disruption of prenylation and phosphorylation of 
signaling proteins.  a) Cellular cholesterol levels. MYC expressing tumor cells were 
analyzed 24 hours after treatment. Equivalent numbers of cells were analyzed when 
MYC was expressed (MYC ON) or not expressed (MYC OFF) after doxycycline 
treatment (20 ng/ml) in the absence or presence of 10 µM atorvastatin (AT), 100 µM 
mevalonate (Mev) or 10 µM atorvastatin plus 100 µM mevalonate (AT + Mev). b) 
Prenylation of several proteins was assessed by immunoblot when treated as described 
above. Treatment with farnesyltransferase inhibitor-277 (FTI-277, 5µM) or 
geranylgeranyltransferase inhibitor-298 (GGTI-298, 5µM) was used as controls to 
visualize changes observed in farnesylation and geranylation, respectively. c) Ras 
protein accumulates in cytoplasm following atorvastatin treatment. MYC-induced 
lymphoma cell lines were treated for 6 hours with atorvastatin (10 mM) (AT). The 
cytoplasmic fraction was isolated and analyzed by Western blot for Ras protein.   
Representative data from one of three experiments is shown.  d) Kinetic analysis of 
changes in phospho-protein expression analyzed by FACS analysis.  MYC-induced 
lymphoma cell lines were treated for 24 and 36 hours, as indicated. The response to 
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atorvastatin (AT), mevalonate (Mev) and atorvastatin with mevalonate (AT+Mev) were 
determined and compared with the basal state, shown in the profile in black. Cells were 
analyzed for changes in phosphorylation of 56 different phospho-protein epitopes. 
Changes observed for 19 of the epitopes are presented. e) FACS plot analysis for 
changes in ERK1/2 phosphorylation. f) Analysis of levels of protein expression and 
phosphorylation. Levels of ERK1/2, phosphorylated-ERK1/2 (pERK1/2), Akt and 
phosphorylated-Akt (pS473) (pAkt) are measured by Western analysis.  
 
Figure 4. Atorvastatin treatment results in the dephosphorylation and inactivation 
of MYC. a) Analysis of levels of MYC protein expression and phosphorylation. Levels 
of MYC and MYC phosphorylated at Ser62 and Thr58 (p-MYC) measured by Western 
analysis. b) Temporal analysis of MYC phosphorylation.  MYC-induced lymphoma 
cell lines  were treated with atorvastatin and analyzed at indicated times for 
phosphorylation of ERK1/2, phosphorylation of MYC and cleavage of caspase 3 by 
FACS. c) Treatment of human Burkitt’s lymphoma cell line ST486 with atorvastatin.  
Levels of pERK1/2, pMYC and cleaved caspase 3 were analyzed by FACS following 
treatment with 10 µM atorvastatin (AT), 100 µM mevalonate (Mev) or 10 µM 
atorvastatin plus 100 µM mevalonate (AT + Mev). d)  Temporal analysis of MYC 
phosphorylation.  MYC-expressing tumor cells (0.3x10^6) were treated with 
atorvastatin (10 µM) for different lengths of time and analyzed for changes in MYC 
phosphorylation and expression of ODC, a known MYC transcriptional target. This 
image was cropped so that the 0 and 6 hour time point were next to each other. e) 
Quantitative real-time PCR analysis of cDNA from MYC lymphoma cells where MYC 
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was expressed (MYC ON) or MYC was inactivated (MYC OFF) after doxycycline 
treatment (20 ng/ml) or in the presence of 10 µM atorvastatin (AT), 100 µM 
mevalonate (Mev) or 10 µM atorvastatin plus 100 µM mevalonate (AT + Mev). 
Expression of each gene was normalized to the expression of ubiquitin. Changes in 
gene expression were measured for each treatment and compared to MYC-expressing, 
non-treated tumor cells. Changes greater than 2 fold are statistically significant, as 
indicated in blue and orange/red (T-test:  p<0.05 - 0.001). 
 
Figure 5. Atorvastatin fails to decrease MYC phosphorylation or induce 
proliferative arrest in K-Ras (G12D) tumors. a) Analysis of pERK1/2 and pMYC 
expression in tumor cells overexpressing MYC together with activated K-Ras (G12D). 
Tumor cells were treated as above and analyzed by Western blot analysis to assess the 
state of phosphorylation of ERK1/2 and MYC. b) Analysis of proliferation of tumor 
cells overexpressing MYC together with activated K-Ras (G12D). Tumor cells were 
treated with doxycycline to inactivate MYC and K-Ras (G12D) expression or treated 
with 10 µM atorvastatin (AT), 100 µM mevalonate (Mev) or 10 µM atorvastatin plus 
100 µM mevalonate (AT + Mev). c) Effect of atorvastatin on cells expressing WT c-
Myc or mutant c-Myc (S62A) or c-Myc (T58A).  HeLa cells were not infected or 
infected with adenovirus containing murine Myc (Ad-Myc
WT) or Myc mutated at S62 
(Ad-Myc
S62A), which prevents Myc phosphorylation and activation, or Myc mutated at 
T58 (Ad-Myc
T58A), which prevents dephosphorylation of Myc’s activation site. Cells 
were treated or not treated with atorvastatin (10 µM). 
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Figure 6. Inactivation of HMGcoA reductase by RNAi was sufficient to induce loss 
of a neoplastic phenotype. a) HMGcoA reductase and pMYC protein expression in 
cells treated with siRNA.  A MYC-induced lymphoma cell line was transfected with 
smart-pool siRNA (Dharmacon RNA Technologies) directed against HMGcoA 
reductase and compared to mock-transfected cells. Protein expression was analyzed 18 
hours after treatment by Western analysis. b) Cell survival upon siRNA knockdown of 
HMGcoA reductase. Cells were stained with trypan blue and analyzed for survival 30 
hours after transfection with siRNA. c,d) Single cell FACS analysis of cells transfected 
with siRNA. Levels of expression of HMGcoA reductase, phosphorylated ERK1/2, and 
phosphorylated MYC after c) control / mock transfection or d) transfection with siRNA 
against HMGcoA reductase, as measured by FACS analysis. Three color clustering of 
cellular populations was performed in FlowJo and unique populations were color 
coded. Cells that do not incorporate the siRNA are blue/purple. Cells that incorporate 
the siRNA are orange.   
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